At 48% of U.S. term life portfolios, automated medical underwriting tools are now the default, not the exception. We put the top platforms through a 90-day pilot for a $500M block of fully underwritten business. Here’s what worked, what didn’t, and where the hidden costs live.

At 48% of U.S. term life portfolios, automated medical underwriting tools are now the default, not the exception. We put the top platforms through a 90-day pilot for a $500M block of fully underwritten business. Here’s what worked, what didn’t, and where the hidden costs live.

I ran the underwriting transformation program at a $20B life carrier for three years. We migrated 48% of in-force term life cases from paper labs to straight-through processing by Q3 2024, and the ROI came in at 3.4x when we counted only realized savings in TAT and human review avoidance—not including mortality lift or anti-selection gains. That pilot validated what I’ve seen across a dozen carriers: automated medical underwriting (AMU) platforms are table stakes now, but the gap between promise and production is brutal. Below is the unvarnished review of four platforms we evaluated side-by-side: Vero, Medicity, Lumino, and Underwrite.ai.

What AMU Actually Does: From Labs to Decision in Minutes

Automated medical underwriting replaces manual review of fluids, APS requests, motor vehicle reports, Rx databases, and prescription histories with a deterministic or ML-driven rules engine that returns a non-rated, rated, or table-rated outcome. The platforms ingest structured lab data (e.g., cholesterol, HbA1c), unstructured physician notes via NLP, and third-party data feeds (Milliman IntelliScript, MIB, LexisNexis, Verisk CLUE).

The critical difference is how each vendor handles the tail risk. Vero and Lumino lean on medical logic rules vetted by reinsurers; Medicity relies on broker-supplied lab data and broker-adjusted rules; Underwrite.ai uses a proprietary ML model trained on 12M+ policies, but the model is opaque—no transparency on feature importance for any given case.

Trade-off: The more deterministic the rules, the faster the cycle time but the higher the manual override rate on edge cases. The more ML-driven, the lower the override rate but the higher the regulatory scrutiny and explainability burden. NAIC’s 2019 Principles for AI Use in Insurance require carriers to document model risk, and the NAIC’s model governance working group just finalized guidance on adverse selection risks in opaque models in March 2024.

Use Case Fit: Which Carrier Segments Benefit Most

I’ve seen carriers try to shoehorn a broker-centric tool like Medicity into a direct-to-consumer flow and hit a 28% override rate because the broker-supplied lab data is inconsistent. Conversely, Underwrite.ai’s 1-2 day cycle time sounds great until you realize their pricing tiers assume 80% straight-through processing—and the remaining 20% require a human review that costs more than the platform savings.

Pricing: Where the Margin Erosion Starts

All four platforms use a per-case fee model, but the devil is in the tiers. Vero charges $15-$35 per case depending on face amount and reinsurance support; Medicity’s broker-facing model is $10-$25 but scales with broker volume; Lumino’s enterprise license starts at $250k annually for unlimited cases with a $5k minimum monthly spend; Underwrite.ai’s Starter tier is $0.25 per case but caps at 25k cases per year, and the Pro tier jumps to $0.18 per case at 1M+ cases—still with a 20% manual review fee baked into the unit economics.

Hidden cost: Data ingestion. Medicity and Lumino require ETL pipelines into broker portals or carrier core systems. My team spent $85k on ETL development and another $42k on third-party data normalization (Milliman IntelliScript extracts). Vero and Underwrite.ai offer pre-built APIs, but Vero’s API has a hard limit of 100 calls per minute—knocking out high-volume flows without a custom queueing layer.

Trade-off: Cheaper per-case pricing usually means higher integration friction. The platforms that bill like utilities (Underwrite.ai) extract value from scale, but carriers with legacy systems pay dearly in engineering hours.

Setup Experience: From Contract to Go-Live in 90 Days or Bust

Medicity was the fastest to pilot—14 days from signed contract to first case submitted—but the platform’s broker-sourced lab data introduced a 19% variance from carrier lab sources. That variance drove up our mortality assumption by 0.3% in the pricing model—erasing most of the projected savings.

Lumino took 78 days to production because their rules engine required 12 custom underwriting guidelines to match our reinsurer’s table ratings. Their documentation claims 30 days, but reinsurer sign-off added three weeks.

Underwrite.ai’s API-first approach meant we could ingest data from our core (Guidewire Life) in five days, but their model drift alerts fired constantly during our QA window. We had to freeze new case intake for three days while we retrained their gradient-boosted model on our book’s lab distributions.

Vero was the only platform that delivered a reinsurer-approved ruleset out of the box. Their medical director pre-vetted every rule against Munich Re and Swiss Re’s underwriting manuals, cutting our internal review time from 40 hours to 12 hours per product line. The downside: their library covers U.S. term only; we had to build custom rules for our Canadian block—adding six weeks and $65k in actuarial consulting.

What Each Platform Does Well (and Poorly)

Vero: The Reinsurer-Backed Rules Engine

• Strengths: Reinsurer-approved rules reduce override rate to 12% across our portfolio. Their API supports real-time underwriting decisions at point of sale, which we used to launch accelerated underwriting on a $500M block without a paper lab. Their documentation is actuarially rigorous—each rule maps to a reinsurer’s manual citation.
• Weaknesses: No support for international markets. Their NLP engine for physician notes is basic—misses nuance in complex comorbidities, leading to a 15% false-negative rate on diabetes cases. Fixing it requires manual rule tweaks at $3k per rule.

I’ve reviewed dozens of AMU tools. Vero is the only one where the reinsurer is the customer—not the carrier. That alignment matters when you’re negotiating mortality tables.

Medicity: The Broker’s Favorite

• Strengths: Brokers love the portal integration. Medicity ingests lab data directly from LabCorp and Quest Diagnostics portals, cutting broker data entry by 60%. Their pricing is transparent and scales with broker volume, making it easy to onboard MGAs.
• Weaknesses: Broker-sourced data is noisy. In our pilot, Medicity’s lab values deviated from our lab vendor’s by ±15% in 22% of cases. We had to build a reconciliation layer that added $28k in development and delayed ROI by six months.

Medicity works if your distribution is 100% broker-driven. If you have a direct or hybrid channel, the data quality gap becomes a liability.

Lumino: The Custom Rulesmith

• Strengths: Lumino’s underwriting rules engine is the most flexible. We modeled niche products like guaranteed issue and simplified issue with custom logic, cutting our manual review rate by 40%. Their NLP for physician notes is strong—92% accuracy on comorbidity extraction compared to human review.
• Weaknesses: The platform is expensive. Their enterprise license starts at $250k annually, and custom rules require actuarial sign-off, adding $15k per rule. Their sales team claimed “30-day implementation” in the pitch deck; we measured 78 days from contract to go-live.

Lumino is the tool for carriers with complex underwriting guidelines. If your underwriting team spends more time arguing over guidelines than pricing risk, Lumino will pay for itself.

Underwrite.ai: The Black Box Challenger

• Strengths: Their ML model hits 89% straight-through processing on first submissions. For digital carriers, that’s a game-changer. They also offer a “pre-fill” API that pulls lab data from EHRs, reducing broker data entry by 70%.
• Weaknesses: Opaque model. We couldn’t get feature importance for a declined 45-year-old male with HbA1c of 6.8. Their explainability report was a 12-page PDF with no actionable insights. Regulatory scrutiny is inevitable.

Underwrite.ai is the riskiest choice. If your actuarial team can’t sign off on model risk, avoid it.

Where the Hidden Costs Live: Integration, Data, and Model Drift

I’ve seen carriers budget $50k for AMU implementation and end up spending $350k. The cost sinks:

• Data Normalization: Milliman IntelliScript returns lab values in six different formats. Normalizing to LOINC codes cost us $85k in consulting fees.
• Rule Reconciliation: Medicity’s lab values didn’t match our lab vendor’s. Reconciling the two added $28k in development.
• Model Drift: Underwrite.ai’s model drifted after three months. We had to retrain it on our book’s lab distributions, costing $45k in actuarial time.
• Reinsurer Sign-off: Vero and Lumino required reinsurer approval for custom rules. The reinsurer’s underwriting team took three weeks per rule set.

Trade-off: The cheaper per-case platforms extract value from scale, but they require heavy engineering lift. The more “out of the box” platforms (Vero) come with reinsurer-approved rules but limit flexibility.

Regulatory and Compliance Risks That No One Talks About

NAIC’s draft Model Bulletin on AI Use in Insurance (2024) requires carriers to document model risk, adverse selection testing, and consumer disclosures. Underwrite.ai’s black-box model will draw scrutiny from every state DOI. Medicity’s broker-sourced lab data introduces fairness risks—brokers may steer healthier applicants to carriers with less stringent lab requirements, creating anti-selection.

I’ve reviewed internal audit findings for three carriers using AMU. The most common finding: failure to document model validation for NLP feature extraction. The second: inadequate adverse selection testing. The NAIC’s March 2024 guidance explicitly calls out AMU as a high-risk use case for anti-selection.

Trade-off: The faster you underwrite, the higher the regulatory and actuarial scrutiny. If your compliance team isn’t looped in from day one, you’re setting yourself up for a model remediation project.

Bottom Line: Which Platform Fits Your Stack?

For large carriers with reinsurance partners and U.S.-only term blocks, Vero is the safest bet. Their reinsurer-approved rules reduce override rates and regulatory risk.

For brokers and MGAs pushing accelerated underwriting, Medicity is the easiest to sell—but expect data quality issues and reconciliation costs.

For carriers with complex underwriting guidelines and niche products, Lumino is the most flexible—but the price tag and implementation timeline are brutal.

For digital-first carriers and InsurTechs, Underwrite.ai delivers the fastest cycle times—but model risk and explainability will haunt you.

Next step: Run a 90-day pilot on a $50M block, not a $500M block. Measure override rates, data quality variance, and integration costs. If the override rate exceeds 15%, walk away. The savings aren’t worth the risk.